FNY Investment Advisers’s Novo Nordisk NVO Stock Holding History

FNY Investment Advisers’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54K	Sell	1,140 -990	-46%	-$42.5K	0.02%	407
2026 Q1	$78K	Buy	2,130 +30	+1%	+$1.42K	0.03%	312
2025 Q4	$106K	Buy	+2,100	New	+$107K	0.03%	333
2025 Q2	–	Sell	-8,972	Closed	-$623K	–	1117
2025 Q1	$623K	Buy	+8,972	New	+$741K	0.38%	67
2023 Q4	–	Sell	-3,000	Closed	-$272K	–	704
2023 Q3	$272K	Buy	+3,000	New	+$264K	0.16%	88
2022 Q4	–	Sell	-80,000	Closed	-$3.98M	–	676
2022 Q3	$3.98M	Buy	+80,000	New	+$4.29M	2.76%	5
2021 Q1	–	Sell	-37,800	Closed	-$1.32M	–	951
2020 Q4	$1.32M	Buy	37,800 +1,200	+3%	+$41.5K	0.36%	65
2020 Q3	$1.27M	Buy	36,600 +24,000	+190%	+$800K	0.54%	51
2020 Q2	$412K	Buy	12,600 +2,600	+26%	+$83K	0.24%	96
2020 Q1	$301K	Buy	+10,000	New	+$298K	0.23%	88
2019 Q4	–	Sell	-10,000	Closed	-$258K	–	992
2019 Q3	$258K	Buy	+10,000	New	+$253K	0.08%	142

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

FNY Investment Advisers's NVO Position: Q2 2026 in Review

FNY Investment Advisers reduced its Novo Nordisk (NVO) stake by 46% in Q2 2026, selling an estimated $42.5K and leaving 1,140 shares worth $54K. The position accounts for 0.02% of the portfolio, ranked #407.

FNY Investment Advisers first reported a position in NVO in Q3 2019 and has held it in 11 quarters since. The position peaked at $3.98M in Q3 2022. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

FNY Investment Advisers held 1,140 shares of Novo Nordisk worth $54K as of Q2 2026.
FNY Investment Advisers sold 990 Novo Nordisk shares in Q2 2026, an estimated $42.5K.
Novo Nordisk made up 0.02% of FNY Investment Advisers's portfolio in Q2 2026, its #407 holding.
FNY Investment Advisers first reported a position in Novo Nordisk in Q3 2019 and has held it in 11 quarters since.
FNY Investment Advisers's Novo Nordisk position peaked at $3.98M in Q3 2022.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.